Earnings Feed
Start Free
Immunome Inc.·4

Jul 2, 8:31 PM ET

Barchas Isaac 4

Research Summary

AI-generated summary

Updated

Immunome (IMNM) Director Isaac Barchas Sells Shares

What Happened
Isaac Barchas, a director (and managing member of related entities), sold a total of 201,050 shares of Immunome common stock in three open‑market dispositions for aggregate proceeds of $4,393,025. The sales were: 101,050 shares on 2026-06-30 at a weighted average price of $21.12 (range $20.83–$21.47) for $2,134,176; 75,665 shares on 2026-07-02 at a weighted average price of $22.35 (range $22.015–$23.015) for $1,691,113; and 24,335 shares on 2026-07-02 at a weighted average price of $23.33 (range $23.03–$23.67) for $567,736. These were sales (not purchases).

Key Details

  • Transaction dates and weighted-average prices:
    • 2026-06-30 — 101,050 sh @ $21.12 (range $20.83–$21.47) = $2,134,176
    • 2026-07-02 — 75,665 sh @ $22.35 (range $22.015–$23.015) = $1,691,113
    • 2026-07-02 — 24,335 sh @ $23.33 (range $23.03–$23.67) = $567,736
  • Total shares sold: 201,050; total proceeds: $4,393,025.
  • Shares owned after transactions: ABHMC (an entity managed by Barchas) owns 308,504 shares. The reporting person disclaims beneficial ownership of the shares held by these entities except to the extent of any pecuniary interest.
  • Notable footnotes:
    • Sales were automatic under Rule 10b5-1 trading plans adopted by ABHMC II LLC and Arsenal Bridge Venture II‑B LLC on March 31, 2026.
    • Some shares sold were by related entities (e.g., 100,000 sold by ABHMC and 1,050 by ABV II‑B as reported).
    • Several footnotes explain that certain shares previously received were pro rata distributions in kind (a change in form of ownership) and thus not reportable as Section 16 acquisitions.
  • Filing: Form 4 filed 2026-07-02 covering transactions through 2026-06-30/07-02; appears to be filed within the typical 2-business‑day window.

Context

  • These were routine sales executed under pre-arranged 10b5-1 plans (not necessarily a contemporaneous personal trading decision). 10b5-1 plans allow scheduled trades and are common for liquidity or diversification.
  • Sales are generally less informative about insider sentiment than purchases; no options were exercised and no gifts or awards are reported here.